-
Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur. Urol. (IF 23.4) Pub Date : 2024-03-16 Michael Baboudjian, Romain Diamand, Alessandro Uleri, Jean-Baptiste Beauval, Alae Touzani, Jean-Baptiste Roche, Vito Lacetera, Thierry Roumeguère, Giuseppe Simone, Daniel Benamran, Alexandre Fourcade, Bastien Gondran-Tellier, Gaelle Fiard, Alexandre Peltier, Guillaume Ploussard
In our multicenter European study involving 1020 patients with Gleason grade group ≥2 prostate cancer on magnetic resonance imaging–targeted biopsy, the rate of downgrading at radical prostatectomy specimen was 17.5%, but the overall risk of targeted biopsy–induced overtreatment was only ∼2.7%. Our findings indicate that targeted biopsy results are accurate and should be used for decision-making without
-
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial Eur. Urol. (IF 23.4) Pub Date : 2024-03-16 John Nikitas, Matthew Rettig, John Shen, Robert Reiter, Alan Lee, Michael L. Steinberg, Luca F. Valle, Ankush Sachdeva, Tahmineh Romero, Jeremie Calais, Johannes Czernin, Nicholas G. Nickols, Amar U. Kishan
In men with prostate-specific membrane antigen–defined, oligorecurrent M1a–b prostate cancer, short-course androgen annihilation therapy and metastasis-directed stereotactic body radiotherapy achieved a substantial disease-free interval following testosterone recovery. This regimen was well tolerated, and 90% of patients completed therapy with androgen deprivation therapy and at least one androgen
-
Corrigendum to “European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines” [Eur. Urol. 85 (2024) 17–31] Eur. Urol. (IF 23.4) Pub Date : 2024-03-15 J. Alfred Witjes, Harman Max Bruins, Albert Carrión, Richard Cathomas, Eva Compérat, Jason A. Efstathiou, Rainer Fietkau, Georgios Gakis, Anja Lorch, Alberto Martini, Laura S. Mertens, Richard P. Meijer, Matthew I. Milowsky, Yann Neuzillet, Valeria Panebiaco, John Redlef, Michael Rink, Mathieu Rouanne, George N. Thalmann, Sæbjørn Sæbjørnsen, Erik Veskimäe, Paramananthan Mariappan, Antoine G. van der
-
Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.09.024 Eur. Urol. (IF 23.4) Pub Date : 2024-03-15 Olivier Cussenot, Antoine Chambaz, Freddie C. Hamdy
-
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study Eur. Urol. (IF 23.4) Pub Date : 2024-03-15 Manuel Weber, Wolfgang P. Fendler, Aravind S. Ravi Kumar, Jeremie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Alexander Kretschmer, Turkay Hekimsoy, Sabine D. Brookman-May, Suneel D. Mundle, Eric J. Small, Matthew R. Smith, Paola M. Perez, Thomas A. Hope, Ken Herrmann, Michael S. Hofman, Matthias Eiber, Boris A. Hadaschik
Use of prostate-specific membrane antigen positron emission tomography to determine disease extent provides a novel method for risk stratification for patients with nonmetastatic castration-resistant prostate cancer and may contribute to future risk-adapted treatment algorithms.
-
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population Eur. Urol. (IF 23.4) Pub Date : 2024-03-14 Rodolfo Montironi, Alessia Cimadamore, Gianluca Giannarini, Alessandro Crestani, Antonio Lopez-Beltran, Liang Cheng
-
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial Eur. Urol. (IF 23.4) Pub Date : 2024-03-14 Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, Rafael Morales-Barrera, Francesco Grussu, Irene Casanova-Salas, Francesco Sanguedolce, Macarena Gonzalez, Pablo Cresta-Morgado, Matias de Albert, Josep Garcia-Bennett, David Marmolejo, Jacques Planas, Sarai Roche, Richard Mast, Christina Zatse, Josep M Piulats, Bernardo Herrera-Imbroda, Lucas Regis, Laura Agundez, David Olmos, Nahum Calvo, Manuel
-
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07) Eur. Urol. (IF 23.4) Pub Date : 2024-03-14 Loig Vaugier, Cyrille Morvan, David Pasquier, Xavier Buthaud, Nicolas Magné, Veronique Beckendorf, Paul Sargos, Gilles Crehange, Pascal Pommier, Genevieve Loos, Ali Hasbini, Igor Latorzeff, Marlon Silva, Julie Paul, Audrey Blanc-Lapierre, Stéphane Supiot
Pelvic radiotherapy offered prolonged tumor control for oligorecurrent prostate cancer in pelvic lymph nodes, and grade 2+ toxicity remained below 15%. Approximately one-third of patients were still in complete remission after 5 yr. Para-aortic lymph nodes were the main sites of relapse.
-
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer Eur. Urol. (IF 23.4) Pub Date : 2024-03-14 Nicholas G. Nickols, Sonny Tsai, Nathanael Kane, Samantha Tran, Leila Ghayouri, Silvia Diaz-Perez, May Thein, Nancy Anderson-Berman, Jeanie Eason, Amar U. Kishan, Michael L. Steinberg, Robert E. Reiter, Steve P. Lee, Greg E. Gin, Robert Kwon, Michael G. Chang, Hann-Hsiang Chao, Abhiskek A. Solanki, Rachael Sexton, Michael Lewis, William Lorentz, Michael K. Cheung, Diana L. Gage, Sai Duriseti, Luca
-
Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial Eur. Urol. (IF 23.4) Pub Date : 2024-03-14 Fredrik Möller, Marianne Månsson, Jonas Wallström, Mikael Hellström, Jonas Hugosson, Rebecka Arnsrud Godtman
In a screening population, a non-negligible number of men with prostate-specific antigen (PSA) 1.8–3.0 ng/ml have clinically significant prostate cancer. Lowering the PSA threshold for magnetic resonance imaging (MRI) would lead to a large increase in MRI examinations, and whether the benefits of lowering the PSA threshold outweigh the harms is not yet known.
-
Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.012 Eur. Urol. (IF 23.4) Pub Date : 2024-03-12 Andrei Fodor, Chiara Brombin, Arturo Chiti, Nadia Di Muzio
-
Re: Katie Gordon, Naomi Warne, Jon Heron, Alexander von Gontard, Carol Joinson. Continence Problems and Mental Health in Adolescents from a UK Cohort. Eur Urol 2023;84:463–70 Eur. Urol. (IF 23.4) Pub Date : 2024-03-08 Wentao Yao, Jiacheng Wu, Yuhua Huang
-
Re: Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence Eur. Urol. (IF 23.4) Pub Date : 2024-03-08 Martijn A.C. Smits, John P.F.A. Heesakkers
-
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy Eur. Urol. (IF 23.4) Pub Date : 2024-02-28 Jonathan E. Rosenberg, Ronac Mamtani, Guru P. Sonpavde, Yohann Loriot, Ignacio Duran, Jae-Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Srikala S. Sridhar, Helle Pappot, Howard Gurney, Jens Bedke, Michiel S. van der Heijden, Luca Galli, Bhumsuk Keam, Naoya Masumori, Johannes Meran, Peter H. O'Donnell, Se Hoon Park, Enrique Grande, Lisa Sengeløv, Hiroji Uemura, Konstantina Skaltsa
In comparison to chemotherapy, enfortumab vedotin (EV) prolonged overall survival in patients with previously treated advanced urothelial carcinoma in EV-301. The objective of the present study was to assess patient experiences of EV versus chemotherapy using patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL). For patients in the phase 3 EV-301 trial randomized to EV
-
Reply to Behnam Shakiba’s Letter to the Editor re: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, et al. Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.020 Eur. Urol. (IF 23.4) Pub Date : 2024-02-22 Emilien Seizilles de Mazancourt, Kevin Kaulanjan
-
Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer Eur. Urol. (IF 23.4) Pub Date : 2024-02-21 Nicolaus F. Debatin, Elena Bady, Tim Mandelkow, Zhihao Huang, Magalie C.J. Lurati, Jonas B. Raedler, Jan H. Müller, Eik Vettorazzi, Henning Plage, Henrik Samtleben, Tobias Klatte, Sebastian Hofbauer, Sefer Elezkurtaj, Kira Furlano, Sarah Weinberger, Paul Giacomo Bruch, David Horst, Florian Roßner, Simon Schallenberg, Andreas H. Marx, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek
-
Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer Eur. Urol. (IF 23.4) Pub Date : 2024-02-19 Bernard Pope, Gahee Park, Edmund Lau, Jelena Belic, Radoslaw Lach, Anne George, Patrick McCoy, Anne Nguyen, Corrina Grima, Bethany Campbell, Chol-hee Jung, Emma-Jane Ditter, Hui Zhao, The Pan Prostate Cancer Group (PPCG), David C. Wedge, Daniel S. Brewer, Andy G. Lynch, Harveer Dev, Vincent J. Gnanpragasam, Nitzan Rosenfeld, Christopher M. Hovens, Niall M. Corcoran, Charles E. Massie
-
Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825–34 Eur. Urol. (IF 23.4) Pub Date : 2024-02-15 Shahrokh F. Shariat, Ekaterina Laukhtina
-
Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial Eur. Urol. (IF 23.4) Pub Date : 2024-02-08 Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, Umberto Anceschi, Alfredo Maria Bove, Aldo Brassetti, Simone D'Annunzio, Leonardo Misuraca, Giulia Torregiani, Marco Covotta, Salvatore Guaglianone, Michele Gallucci, Giuseppe Simone
Findings from this first randomised trial comparing robot-assisted radical cystectomy (RARC) with totally intracorporeal urinary diversion to open RC confirm that it is a safe surgical option. The transfusion rate was 50% lower, while complication rates and 3-yr oncological outcomes were comparable to those for open RC. The probabilities of daytime and night-time continence recovery were comparable
-
Re: Evaluating the Safety of Same-day Discharge Following Pediatric Pyeloplasty and Ureteral Reimplantation; A NSQIP Analysis 2012–2020 Eur. Urol. (IF 23.4) Pub Date : 2024-01-30 Vasileios Tatanis, Evangelos Liatsikos
Abstract not available
-
Circulating Tumour DNA Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients Eur. Urol. (IF 23.4) Pub Date : 2024-02-01 Faisal S. BinHumaid, Anshita Goel, Naheema S. Gordon, Ben Abbotts, K.K. Cheng, Maurice P. Zeegers, Nicholas D. James, Waleed M. Altaweel, Raouf M. Seyam, Brian F. Meyer, Roland Arnold, Douglas G. Ward, Richard T. Bryan
Abstract not available
-
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Eur. Urol. (IF 23.4) Pub Date : 2024-01-29 Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, J. Connor Wells, Renee Maria Saliby, Talal El Zarif, Chris Labaki, Naveen S. Basappa, Bernadett Szabados, Thomas Powles, Ian D. Davis, Lori A. Wood, Aly-Khan A. Lalani, Rana R. McKay, Jae-Lyun Lee, Luis Meza, Sumanta K. Pal, Frede Donskov, Takeshi Yuasa, Benoit Beuselinck, Daniel Y.C. Heng
Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy. First-line
-
Thulium Fiber Laser Versus Holmium:Yttrium Aluminum Garnet for Lithotripsy: A Systematic Review and Meta-analysis Eur. Urol. (IF 23.4) Pub Date : 2024-01-29 Alessandro Uleri, Alba Farré, Paula Izquierdo, Oriol Angerri, Andrés Kanashiro, Josep Balaña, Vineet Gauhar, Daniele Castellani, Francisco Sanchez-Martin, Manoj Monga, Adolfo Serrano, Mantu Gupta, Michael Baboudjian, Andrea Gallioli, Alberto Breda, Esteban Emiliani
Context Thulium fiber laser (TFL) emerged as a competitor of holmium:yttrium aluminum garnet (Ho:YAG) laser for the treatment of urinary stones. Objective To compare the efficacy between Ho:YAG and TFL for laser lithotripsy of renal and ureteral stones. Evidence acquisition A literature search was conducted using PubMed/Medline, Embase, and Web of Science databases to identify reports published until
-
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774) Eur. Urol. (IF 23.4) Pub Date : 2024-01-29 Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, Tristan R. Grogan, David Elashoff, Ethan C. Lam, Kevyn J. Clark, Michael L. Steinberg, Wolfgang P. Fendler, Thomas A. Hope, Nicholas G. Nickols, Johannes Czernin, Jeremie Calais
Background Both imaging and several prognostic factors inform the planning of salvage radiotherapy (SRT). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can localize disease unseen by other imaging modalities. Objective To evaluate the impact of PSMA-PET on biochemical recurrence–free survival rate after SRT. Design, setting, and participants This prospective randomized
-
Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2–4 Prostate Cancer Eur. Urol. (IF 23.4) Pub Date : 2024-01-25 Andrew J. Vickers, Melissa Assel, Matthew R. Cooperberg, Samson W. Fine, Scott Eggener
Abstract not available
-
Re: What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel Eur. Urol. (IF 23.4) Pub Date : 2024-01-26 Pradeep Tyagi, Michael Chancellor
Abstract not available
-
Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data Eur. Urol. (IF 23.4) Pub Date : 2024-01-25 Fredrik Liedberg, Johannes Bobjer
Abstract not available
-
The Elusive Horizon: Biomarkers in Urothelial Carcinoma Eur. Urol. (IF 23.4) Pub Date : 2024-01-25 Joshua A. Linscott, Joshua J. Meeks, Lars Dyrskjøt, Roger Li
Abstract not available
-
Reply to Carmen Gravina, Matteo Romagnoli, Antonio Nacchia, et al.’s Letter to the Editor re: Edward Lambert, Emmanuel Chartier-Kastler, Christophe Vaessen, et al. Robot-assisted Periprostatic Artificial Urinary Sphincter Implantation in Men with Neurogenic Stress Urinary Incontinence: Description of the Surgical Technique and Comparison of Long-term Functional Outcomes with the Open Approach. Eur Eur. Urol. (IF 23.4) Pub Date : 2024-01-23 Edward Lambert, Emmanuel Chartier-Kastler, Christophe Vaessen, Aurélien Beaugerie, Juliette Cotte, Morgan Rouprêt, Pierre Mozer, Jérôme Parra, Thomas Seisen, Louis Lenfant
Abstract not available
-
Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. Eur Urol 2023;84:393–405 Eur. Urol. (IF 23.4) Pub Date : 2024-01-24 Philipp Dahm, Onuralp Ergun, Niranjan Sathianathen
Abstract not available
-
-
-
-
-
Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial Eur. Urol. (IF 23.4) Pub Date : 2024-01-11 Jim C. Hu, Melissa Assel, Mohamad E. Allaf, Behfar Ehdaie, Andrew J. Vickers, Andrew J. Cohen, Benjamin T. Ristau, David A. Green, Misop Han, Michael E. Rezaee, Christian P. Pavlovich, Jeffrey S. Montgomery, Keith J. Kowalczyk, Ashley E. Ross, Shilajit D. Kundu, Hiten D. Patel, Gerald J. Wang, John N. Graham, Jonathan E. Shoag, Ahmed Ghazi, Edward M. Schaeffer
Background and objective The transrectal biopsy approach is traditionally used to detect prostate cancer. An alternative transperineal approach is historically performed under general anesthesia, but recent advances enable transperineal biopsy to be performed under local anesthesia. We sought to compare infectious complications of transperineal biopsy without antibiotic prophylaxis versus transrectal
-
A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non–muscle-invasive Bladder Cancer Eur. Urol. (IF 23.4) Pub Date : 2024-01-11 Seon-Kyu Kim, Young Joon Byun, Seong-Hwan Park, Xuan-Mei Piao, Chuang-Ming Zheng, Seongmin Moon, Kyeong Kim, Sun Jin Song, Ho Won Kang, Won Tae Kim, Ok-Jun Lee, Yung Hyun Choi, Sung-Kwon Moon, Wun-Jae Kim, Young Deuk Choi, Seon-Young Kim, Seok Joong Yun
Abstract not available
-
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer Eur. Urol. (IF 23.4) Pub Date : 2024-01-05 Filippo Pederzoli, Michela Riba, Chiara Venegoni, Laura Marandino, Marco Bandini, Elisa Alchera, Irene Locatelli, Daniele Raggi, Patrizia Giannatempo, Paolo Provero, Dejan Lazarevic, Marco Moschini, Roberta Lucianò, Andrea Gallina, Alberto Briganti, Francesco Montorsi, Andrea Salonia, Andrea Necchi, Massimo Alfano
Neoadjuvant pembrolizumab has been shown to be a valid treatment for patients affected by muscle-invasive bladder cancer (MIBC), as demonstrated in the PURE-01 clinical trial (NCT02736266). Among the tumor-extrinsic factors influencing immunotherapy efficacy, extensive data highlighted that the microbiome is a central player in immune-mediated anticancer activity. This report aimed to investigate the
-
Prostate-specific Membrane Antigen–targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution Eur. Urol. (IF 23.4) Pub Date : 2024-01-04 Oliver Sartor
Abstract not available
-
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer Eur. Urol. (IF 23.4) Pub Date : 2024-01-06 Kim N. Chi, Andrew J. Armstrong, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Johann S. de Bono, Nabil Adra, Rohan Garje, Jeff M. Michalski, Mette M. Kempel, Karim Fizazi, Michael J. Morris, Oliver Sartor, Marcia Brackman, Michelle DeSilvio, Celine Wilke, Geoffrey Holder, Scott T. Tagawa
We show that longer exposure to Lu-PSMA-617 treatment for up to six cycles was not associated with greater toxicity risk. Safety analyses support a favourable benefit-risk profile for six cycles of Lu-PSMA-617 in patients with progressive, prostate-specific membrane antigen–positive, metastatic castration-resistant prostate cancer.
-
Update and Summary of the European Association of Urology/European Society of Paediatric Urology Paediatric Guidelines on Vesicoureteral Reflux in Children Eur. Urol. (IF 23.4) Pub Date : 2024-01-05 Michele Gnech, Lisette 't Hoen, Alexandra Zachou, Guy Bogaert, Marco Castagnetti, Fardod O'Kelly, Josine Quaedackers, Yazan F. Rawashdeh, Mesrur Selcuk Silay, Uchenna Kennedy, Martin Skott, Allon van Uitert, Yuhong Yuan, Christian Radmayr, Berk Burgu
Background and objective The prescriptive literature on vesicoureteral reflux (VUR) is still limited and thus the level of evidence is generally low. The aim of these guidelines is to provide a practical approach to the treatment of VUR that is based on risk analysis and selective indications for both diagnostic tests and interventions. We provide a 2023 update on the chapter on VUR in children from
-
Reply to Rui-Cheng Wu, Deng-Xiong Li, and De-Chao Feng’s Letter to the Editor re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.014 Eur. Urol. (IF 23.4) Pub Date : 2024-01-05 Michael Eppler, Conner Ganjavi, Andre Abreu, Inderbir Gill, Giovanni E. Cacciamani
Abstract not available
-
Re: Edward Lambert, Emmanuel Chartier-Kastler, Christophe Vaessen, et al. Robot-assisted Periprostatic Artificial Urinary Sphincter Implantation in Men with Neurogenic Stress Urinary Incontinence: Description of the Surgical Technique and Comparison of Long-term Functional Outcomes with the Open Approach. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.09.025 Eur. Urol. (IF 23.4) Pub Date : 2024-01-03 Carmen Gravina, Matteo Romagnoli, Antonio Nacchia, Riccardo Lombardo, Giorgio Franco, Alessandro Giammò, Cosimo De Nunzio
Abstract not available
-
Corrigendum to “Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial” [Eur. Urol. 83(2) (2023) 154–162] Eur. Urol. (IF 23.4) Pub Date : 2024-01-03 Vladimir Student, Zbynek Tudos, Zuzana Studentova, Ondrej Cesak, Hana Studentova, Vaclav Repa, Dana Purova, Vladimir Student
Abstract not available
-
Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] Eur. Urol. (IF 23.4) Pub Date : 2024-01-03 Matthew D. Galsky, Dean F. Bajorin, Johannes Alfred Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begoña P. Valderrama, Marc-Oliver Grimm, Leonard Appleman, Gwenaelle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind-Rotolo, Joshua Zhang, Keziban Ünsal-Kaçmaz
Abstract not available
-
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.014 Eur. Urol. (IF 23.4) Pub Date : 2023-12-26 Rui-Cheng Wu, Deng-Xiong Li, De-Chao Feng
Abstract not available
-
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.014 Eur. Urol. (IF 23.4) Pub Date : 2023-12-23 Zhongwei Zhao, Zhenye Li, Nengwang Yu
Abstract not available
-
Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer Eur. Urol. (IF 23.4) Pub Date : 2023-12-23 Priyanka Yolmo, D. Robert Siemens, Madhuri Koti
Abstract not available
-
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108 Eur. Urol. (IF 23.4) Pub Date : 2023-12-21 Miao Liu, Peng Chen, Tao Li
Abstract not available
-
Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes Eur. Urol. (IF 23.4) Pub Date : 2023-12-16 Matteo Corpetti, Cristina Müller, Himisha Beltran, Johann de Bono, Jean-Philippe Theurillat
Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein overexpressed in most prostate cancers and exploited as a target for PSMA-targeted therapies. Different approaches to target PSMA-expressing cancer cells have been developed, showing promising results in clinical trials. Objective To discuss the regulation of PSMA expression and the main PSMA-targeted therapeutic concepts
-
Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program Eur. Urol. (IF 23.4) Pub Date : 2023-12-15 Peter Albers, Hendrik van Poppel
Abstract not available
-
-
-
-
-
Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491–502 Eur. Urol. (IF 23.4) Pub Date : 2023-12-12 Madhur Anand, Bela Jain, Swati Aggarwal
Abstract not available
-
Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur Urol 2024:85:105–111 Eur. Urol. (IF 23.4) Pub Date : 2023-12-16 Tian-Bao Huang, Xue-Fei Ding
Abstract not available
-
The Metaverse in Minimally Invasive Partial Nephrectomy: Are We There Yet? Eur. Urol. (IF 23.4) Pub Date : 2023-12-14 Weixin Si, Yuqi Tong, Pheng Ann Heng
Abstract not available
-
Reply to Giovanni Lughezzani, Paolo Casale, and Laura Evangelista’s Letter to the Editor re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.07.013 Eur. Urol. (IF 23.4) Pub Date : 2023-12-12 Giuseppe Basile, Andrea Gallioli, Arturo Chiti, Umberto Capitanio, Alberto Breda
Abstract not available
-
Antimicrobial Resistance Patterns in Children with Continuous Antibiotic Prophylaxis: A Meta-analysis of Randomised Controlled Trials Eur. Urol. (IF 23.4) Pub Date : 2023-12-12 Ophelia Aubert, Martin Lacher, Jens-Uwe Stolzenburg, Caelán Haney
Abstract not available
-
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer Eur. Urol. (IF 23.4) Pub Date : 2023-12-12 Wolfgang Beckabir, Sara E. Wobker, Jeffrey S. Damrauer, Bentley Midkiff, Gabriela De la Cruz, Vladmir Makarov, Leah Flick, Mark G. Woodcock, Petros Grivas, Marc A. Bjurlin, Michael R. Harrison, Benjamin G. Vincent, Tracy L. Rose, Shilpa Gupta, William Y. Kim, Matthew I. Milowsky
Background Platinum-based neoadjuvant chemotherapy (NAC) is standard for patients with muscle-invasive bladder cancer (MIBC). Pathologic response (complete: ypT0N0 and partial: